VistaGen Therapeutics, Inc. Investing cash flow

Investing cash flow of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Investing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Investing cash flow for the quarter ending December 30, 2020 was $-151 Thousand (a 52.94% increase compared to previous quarter)
  • Year-over-year quarterly Investing cash flow decreased by -Infinity%
  • Annual Investing cash flow for 2019 was $-174 Thousand (a 10775.0% increase from previous year)
  • Annual Investing cash flow for 2018 was $-1.6 Thousand (a -99.33% decrease from previous year)
  • Annual Investing cash flow for 2017 was $-239 Thousand (a 809.13% increase from previous year)
  • Twelve month Investing cash flow ending December 30, 2020 was $-254 Thousand (a 7.03% increase compared to previous quarter)
  • Twelve month trailing Investing cash flow increased by 49.65% year-over-year
Trailing Investing cash flow for the last four month:
30 Dec '20 29 Sep '20 30 Mar '19 30 Dec '18
$-254 Thousand $-237 Thousand $-174 Thousand $-170 Thousand
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Investing cash flow of VistaGen Therapeutics, Inc.

Most recent Investing cash flowof VTGN including historical data for past 10 years.

Interactive Chart of Investing cash flow of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Investing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-0.15 $-0.1
2019 $-0.0 $-0.17
2018 $0.0 $-0.13 $-0.04 $0.0 $-0.0
2017 $0.0 $-0.0 $-0.23 $-0.24
2016 $-0.0 $-0.01 $-0.0 $-0.02 $-0.03
2015 $-0.0
2014 $0.0 $-0.01
2013 $0.02 $-0.02 $-0.01 $-0.0 $-0.14
2012 $-0.13 $-0.02 $-0.03
2011 $-0.01 $-0.01 $-0.06 $-0.06
2010 $0.0 $-0.01

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.